MAZE THERAPEUTICS INC (MAZE)
Health Care · Clinical-stage biopharmaceutical research and development · NASDAQ
Maze Therapeutics leverages human genetics data and its Compass platform to discover and develop novel therapeutic candidates across multiple disease indications.
What MAZE THERAPEUTICS INC does
Maze Therapeutics is a clinical-stage biopharmaceutical company that uses human genetics data and proprietary target discovery platform called Compass to identify new therapeutic targets and advance them into clinical development. The company focuses on validating therapeutic targets across multiple disease indications and developing drug candidates such as MZE829 and MZE782. Maze operates by combining genomic insights with clinical development to address large addressable markets in therapeutic areas where unmet medical needs exist.
Themes: Genetics-driven drug discovery, Clinical-stage biopharmaceuticals, Precision medicine / genomic medicine, Drug development platform, Clinical-stage biopharmaceuticals / genetics-based drug discovery
Fundamentals
- Price$29.43 as of 2026-08-21 close
- Market cap$1.6B as of 2026-08-21
- 1-year return+122.4% 2025-08-21 close $13.23 → 2026-08-21 close $29.43
- P/En/a negative earnings
- Net margin+11.0% as of 2026-08-24
- ROE-36.6% as of 2026-08-24
- Debt / equity0.11 as of 2026-08-24
- Beta1.21 as of 2026-08-24
- Last reported earnings2026-08-11 SEC EDGAR Form 8-K (Item 2.02)
How MAZE compares in its sector
- net profit margintop 25% 504 covered Health Care peers, as of 2026-08-24
- operating margintop 10% 504 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How MAZE THERAPEUTICS INC looks technically
MAZE THERAPEUTICS INC (MAZE) is trading 15.2% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 56 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 13, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 57, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 4 trading days ago (its momentum flipped positive). It made a new 20-day high about 3 trading days ago. It is 45.1% below its highest point of the past year.
Trend
7
| Distance from the 200-day | it is trading 15.2% below its 200-day average, the long-term trend line — a long-term downtrend | -15.2% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $28.13 | $28.13 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $34.69 | $34.69 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 14 calendar days ago — the swings before that are what the structure reading is measured on | 14 sessions |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 56 trading days ago — a "death cross", a bearish long-term signal | 56 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 13, below the 25 that marks a real trend) | 12.6 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 57, neither overbought (above 70) nor oversold (below 30) | 57.0 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($26.16 to $30.18) — its "stochastic" reading is 81 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 81.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 4 trading days ago (its momentum flipped positive) | 4 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $53.65 | $53.65 |
|---|---|---|
| From the 52-week high | it is 45.1% below its 52-week high (its highest price of the past year) | -45.1% |
| Above the 52-week low | it is 129.7% above its 52-week low (its lowest price of the past year) | +129.7% |
| Below the 52-week high | it is 45.1% below its highest point of the past year | 45.1% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 34 trading days ago | 34 sessions |
| All-time high | its highest closing price on record is $53.65 (set on 2026-03-16) | $53.65 |
| Given back of the 52-week move | over the past year its closes ranged ($13.14 to $51.84), and it has given back a bit over half of its rise from last year’s low — 58% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $26.68 to $27.92. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 57.9% |
| From the all-time high | it is 45.1% below its all-time high | -45.1% |
| Nearest price level | it is trading 1.3% above a support level at $29.04 — a price it turned at twice since 2026-04-22, most recently on 2026-08-07. Since 2025-01-31 it has 6 such levels below the current price and 2 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.3% |
| All-time low | its lowest closing price on record is $6.72 (set on 2025-04-09) | $6.72 |
| Above the all-time low | it is 337.9% above its all-time low | +337.9% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 77% of it) | 23rd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.46 between its high and its low — about 5.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.46 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $26.42 and $29.63 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $26.42 – $28.02 – $29.63 |
| Typical daily range (% of price) | its price moves about 5.0% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.0% |
| Stretch from the 200-day average | it is trading 3.6 daily ranges below its 200-day average price (15.2% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.6 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.72× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
2
| Since a doji | 2 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 2 sessions ago |
|---|---|---|
| Since a bullish engulfing | 4 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 4 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.2% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +0.2% |
|---|---|---|
| Open gap | it gapped 2.7% above the previous close 44 sessions ago and has not traded back through the level it left behind at 24.84 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.7% |
| Gap filled | a 7.5% gap down opened on 2026-06-09 has been "filled" 44 sessions ago — price traded back through the level the gap left behind, and it took 7 sessions to close | 44 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 1.9 percentage points (the stock gained 0.4% while the market gained 2.3%) | -1.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 11.2 percentage points (the stock gained 14.3% while the market gained 3.1%) | +11.2% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 44.5 percentage points (the stock lost 33.4% while the market gained 11.1%) | -44.5% |
| vs market, 12 months | over the past 12 months this stock beat the market by 102.0 percentage points (the stock gained 122.4% while the market gained 20.5%) | +102.0% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a fresh 20-day high, MACD momentum is positive, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months, near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 1.4% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 3.1% of the share price. | +1.4% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 12% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $33.38 — a volume-weighted average of daily closes over 150 sessions, not a true tick-by-tick VWAP. | -11.8% |
|---|
Price levels it has turned at before
MAZE last closed at $29.43 on 2026-08-21. Since 2025-01-31 it has turned at 6 prices below its last close and 2 above; the 3 nearest below and the 2 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $29.04 | Support | 1.3% below the last close | turned there twice · 2026-04-22 to 2026-08-07 |
| $28.27 | Support | 3.9% below the last close | turned there twice · 2025-09-26 to 2026-05-04 |
| $26.27 | Support | 10.8% below the last close | turned there twice · 2026-04-10 to 2026-07-16 |
| $42.81 | Resistance | 45.5% above the last close | turned there five times · 2025-12-04 to 2026-03-09 |
| $49.01 | Resistance | 66.5% above the last close | turned there twice · 2026-02-05 to 2026-02-13 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · Broke out to a new 20-day high · MACD just crossed bullish (12/26/9) · trendless / choppy (low ADX) · lagging the market | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.08 mean, 1=Strong Buy…5=Strong Sell) — 11 analysts
- Mean price target$62.55 range $46.00 – $110.00; median $55.00
Analyst estimates, as of 2026-08-22. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for MAZE
- Consensus EPS estimate-$0.7458 next reporting period, as of 2026-08-22
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical trial timing and regulatory approval risks: The company's success depends on timely initiation and completion of preclinical studies and clinical trials for MZE829, MZE782, and other candidates, as well as obtaining and maintaining regulatory approvals, which are uncertain and costly.","Dependence on third-party relationships and human genetics data: Maze relies on third-party CROs, CMOs, suppliers and manufacturers, and on maintaining access to human genetics data, which could be disrupted or limited, impacting its ability to develop and validate therapeutic targets.","Competitive and regulatory landscape: The company operates in a competitive and rapidly changing environment with extensive government regulations in the US and foreign countries, and faces risks from existing competitors and new market entrants that could impact its ability to compete effectively and achieve market acceptance of therapeutic candidates."]
What changed in the latest 10-Q
AI-assisted comparison of MAZE's 10-Q filed 2026-05-12 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-12) adds: reference to 2025 Form 10-K filed March 25, 2026 instead of 2024 Form 10-K
- Newer filing adds: detailed description of MZE829 Phase 2 trial initiation (November 2024), first patient dosed (February 2025), and March 2026 positive topline proof-of-concept results with 15 patients enrolled
- Newer filing adds: MZE829 demonstrated clinically meaningful mean reduction in proteinuria measured by urinary albumin-to-creatinine ratio
- Newer filing adds: MZE829 was generally well tolerated with no serious adverse events or severe treatment-related adverse events
- Newer filing adds: plan to continue MZE829 Phase 2 enrollment and advance into pivotal development program with additional data expected in late 2026 or early 2027
- Newer filing adds: MZE782 Phase 2 proof-of-concept trial initiation plans for PKU patients by mid-2026 and CKD patients in second half of 2026
- Newer filing adds: anticipated MZE782 Phase 2 topline data from PKU trial in 2027
- Newer filing adds: specific three-month net loss figures of $24.2 million (March 31, 2026) and $32.8 million (March 31, 2025)
- Newer filing adds: accumulated deficit of $513.8 million as of March 31, 2026
- Newer filing adds: cash, cash equivalents and marketable securities of $362.9 million as of March 31, 2026
- Removed:
- Older filing (2025-11-06) includes: obesity mentioned as disease area ('kidney and metabolic diseases, including obesity')
- Older filing describes variant characterization as 'in disease' and linking to 'biological pathways' versus newer filing's 'associated with health and disease' and 'determine how these drive risk'
- Older filing states programs as 'lead programs' versus newer filing's 'clinical programs'
- Older filing states: 'we have not generated any revenue from product sales and we do not expect to generate any revenue' followed by exception clause about license agreements
- Older filing includes: 'Except for the one-time, nonrefundable upfront payments' language structuring revenue discussion differently
- Older filing states: 'except for the net income and cash provided by operations due to license revenue recognized during the year ended December 31, 2024'
- Older filing reports: nine-month net loss of $96.6 million and nine-month net income of $81.8 million for September 30, 2024
- Older filing reports: accumulated deficit of $455.0 million as of September 30, 2025
- Older filing reports: cash, cash equivalents and marketable securities of $383.9 million as of September 30, 2025
- Older filing details: February 2025 IPO with 8,750,000 shares at $16.00 per share for $140.0 million gross proceeds
- Older filing details: September 2025 private placement with 4,000,002 common shares and 5,231,090 pre-funded warrants for $150.0 million gross proceeds
- Older filing mentions: $50.0 million line of credit from loan and security agreement with no drawdown to date
- Older filing ends with phrase: 'We cannot assure you that we will ever be profitable' (versus newer 'we will ever be profitable')
- Older filing includes: description of Broadwing spin-out company ownership (~48%) and convertible note dilution expectations
- Reworded:
- Older: 'identify and characterize genetic variants in disease' changed to newer: 'identify and characterize genetic variants associated with health and disease'
- Older: 'link those variants to the biological pathways that drive disease' changed to newer: 'determine how these drive risk for and protection against disease'
- Older: 'two wholly-owned lead programs' changed to newer: 'two wholly-owned clinical programs'
- Older: financing mentioned as 'equity and convertible promissory notes, debt financing' changed to newer: 'equity and convertible promissory notes' with debt financing de-emphasized in context of license agreements
- Older: 'we have financed our operations primarily through issuances of our equity, license agreements with biotechnology companies and issuances of convertible promissory notes' changed to newer: 'equity and convertible promissory notes, debt financing, as well as...upfront payments...license agreements'
- Older phrase 'we cannot assure you' changed to newer 'we cannot assure' in final sentence
- Notes:
- Older filing text appears truncated at end ('The Phase 1 trial of MZE782 was a randomized, double-blind...'); newer filing also appears truncated ('de'); comparison limited to complete sections available
- Time periods differ significantly: newer filing reports March 31, 2026 quarter-end results while older filing reports September 30, 2025 quarter-end results, making period-to-period comparisons not directly comparable
- Newer filing removes specific details about IPO and private placement financing that were newly completed events in older filing period
Risk Factors
- Added:
- Newer filing added explicit reference to 'or the Private Securities Litigation Reform Act of 1995' as standalone phrase in forward-looking statements section (filed 2026-05-12)
- Removed:
- Older filing stated 'These statements are within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995' which was removed in newer filing (filed 2025-11-06)
- Reworded:
- Opening sentence restructured: newer version states 'These statements appear throughout this Quarterly Report on Form 10-Q and are statements regarding our intent, belief, or current expectations' immediately after Act references, whereas older version had 'In some cases, you can identify forward-looking statements' as the next sentence after the Acts (filed 2026-05-12 vs 2025-11-06)
- Section heading changed from 'Risk Factor Summary' (older, filed 2025-11-06) to 'Summary of Risk Factors' (newer, filed 2026-05-12)
- Duplicate language removed: newer version removed the repetition 'These statements appear throughout this Quarterly Report on Form 10-Q and are statements regarding our intent, belief, or current expectations, primarily with respect to our business and related industry developments' that appeared twice in older version (filed 2026-05-12)
- Notes:
- Both filings are truncated at the end of the Risk Factor Summary section, so comparison of full Risk Factors content is not possible
- Page number references changed (Item 1A page 27 in newer vs page 31 in older; Items 2-6 pages shifted accordingly) but these are formatting changes, not content changes
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 20 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 6 sells ($1M) — 2 selling insiders
- Last 90 days0 buys · 20 sells ($4M) — 3 selling insiders
- Last 180 days0 buys · 27 sells ($6M) — 3 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-03. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about MAZE's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding MAZE as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 4,896,375
- Reported value $146,156,795
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
MAZE had 5,678,545 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
MAZE had 10.2% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 15.88 days to cover at the same settlement.
- Reported short interest (shares) 5,678,545
- Short interest (% of shares outstanding) 10.2%
- Prior settlement (shares) 5,525,278
- Reported change 2.77%
- Days to cover (reported) 15.88
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Frequently asked questions
What does MAZE THERAPEUTICS INC (MAZE) do?
Maze Therapeutics is a clinical-stage biopharmaceutical company that uses human genetics data and proprietary target discovery platform called Compass to identify new therapeutic targets and advance them into clinical development. The company focuses on validating therapeutic targets across multiple disease indications and developing drug candidates such as MZE829 and MZE782.
What sector is MAZE THERAPEUTICS INC (MAZE) in?
MAZE THERAPEUTICS INC (MAZE) is classified in the Health Care sector. Its industry is Clinical-stage biopharmaceutical research and development. It trades on NASDAQ.
Is MAZE THERAPEUTICS INC (MAZE) overbought or oversold right now?
MAZE THERAPEUTICS INC (MAZE) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 57, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on MAZE come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.